Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Fu...
Publications
2 shownAssociation of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
In this meta-analysis, SGLT2 inhibitors were associated with a reduced risk of major adverse CV events; in addition, results suggest significant heterogeneity in associations wi...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 2,466
- Institution
- Pfizer (United States)
External Links
Identifiers
- ORCID
- 0000-0002-5815-6193
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.